Overview

* Stoke Therapeutics ( STOK ) Q3 revenue grows to $10.6 mln, beating analyst expectations

* Net loss for Q3 2025 was $38.3 mln, compared to $26.4 mln in Q3 2024

* Company progressing with Phase 3 EMPEROR study for zorevunersen

Outlook

* Stoke plans to complete Phase 3 EMPEROR study enrollment by H2 2026

* Company to meet FDA by year-end 2025 for expedited zorevunersen approval

* Stoke to activate European sites for STK-002 study in early 2026

Result Drivers

* CONTRACTUAL AGREEMENTS - Revenue increase driven by obligations under agreements with Acadia and Biogen

* FINANCIAL POSITION - Strong cash reserves allowing investment in business and pipeline expansion

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $10.63 $6.16

Revenue mln mln (10

Analysts

)

Q3 Net -$38.34

Income mln

Q3 $53.72

Operatin mln

g

Expenses

Q3 -$43.09

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Stoke Therapeutics Inc ( STOK ) is $30.00, about 13% above its November 3 closing price of $26.10

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)